McKesson Corporation $MCK Shares Sold by CX Institutional

Key Points

• CX Institutional cut its McKesson stake by 50.5% in the third quarter, selling 7,802 shares and retaining 7,661 shares valued at approximately $6.54 million. Institutional investors collectively own 85.07% of the company.
• McKesson extended its pharmaceutical distribution agreement with CVS through June 2032 and reaffirmed fiscal 2027 adjusted EPS guidance of $44.20–$45.00, supporting revenue visibility and investor confidence.
• Recent operating results exceeded expectations, with revenue up 7.7% year over year to $105.38 billion and adjusted EPS of $9.93. Analysts maintain a “Moderate Buy” consensus, while insider selling and the stock’s elevated valuation remain potential risks.

CX Institutional decreased its position in shares of McKesson Corporation (NYSE:MCK - Free Report) by 50.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,661 shares of the company's stock after selling 7,802 shares during the period. CX Institutional's holdings in McKesson were worth $6,541,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MCK. Investment Research Partners LLC grew its position in McKesson by 0.7% during the 4th quarter. Investment Research Partners LLC now owns 1,624 shares of the company's stock worth $1,332,000 after acquiring an additional 11 shares during the last quarter. Anchyra Partners LLC boosted its position in McKesson by 1.0% during the 1st quarter. Anchyra Partners LLC now owns 1,174 shares of the company's stock worth $1,016,000 after buying an additional 12 shares during the period. SJS Investment Consulting Inc. boosted its position in McKesson by 7.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 172 shares of the company's stock worth $149,000 after buying an additional 12 shares during the period. SMART Wealth LLC grew its holdings in McKesson by 3.4% during the 1st quarter. SMART Wealth LLC now owns 366 shares of the company's stock worth $317,000 after acquiring an additional 12 shares during the last quarter. Finally, Stephens Inc. AR grew its holdings in McKesson by 0.8% during the 1st quarter. Stephens Inc. AR now owns 1,581 shares of the company's stock worth $1,368,000 after acquiring an additional 12 shares during the last quarter. Institutional investors own 85.07% of the company's stock.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: CVS partnership extended through June 2032: McKesson reached an agreement to continue distributing pharmaceuticals for CVS’s mail-order, specialty and retail pharmacies, as well as distribution centers. The multiyear extension provides greater revenue visibility and reinforces a strategically important customer relationship. McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
• Positive Sentiment: Fiscal 2027 guidance reaffirmed: McKesson maintained adjusted EPS guidance of $44.20 to $45.00, broadly consistent with the $44.65 analyst consensus. The lack of a guidance reduction helped support investor confidence in operating momentum. McKesson Extends CVS Health Pact to 2032
• Positive Sentiment: Strong recent results and growth initiatives: Investors may also be carrying forward confidence from McKesson’s latest quarter, which included $105.4 billion in revenue and adjusted EPS of $9.93, up 20% year over year. The planned $2.25 billion acquisition of Precision Medicine Group further expands the company’s oncology and clinical research capabilities.
• Neutral Sentiment: Industry backdrop remains constructive: McKesson was included among medical and dental supply stocks viewed as having potential as industry prospects improve. The company is scheduled to report fiscal second-quarter results after the market close on November 4, creating a possible near-term catalyst.
• Negative Sentiment: Insider selling is a risk signal: Reported insider activity over the past six months consisted of 11 sales and no open-market purchases, including sales by CEO Brian Tyler. This may temper enthusiasm, although the transactions did not appear to outweigh the positive CVS announcement.

McKesson Price Performance

Shares of McKesson stock opened at $903.14 on Friday. The business has a 50-day simple moving average of $880.02 and a 200 day simple moving average of $833.60. McKesson Corporation has a one year low of $723.68 and a one year high of $999.00. The firm has a market capitalization of $105.30 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 1.79 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. During the same quarter in the prior year, the company earned $8.26 earnings per share. The company's quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, sell-side analysts expect that McKesson Corporation will post 44.64 EPS for the current year.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. This is an increase from McKesson's previous quarterly dividend of $0.82. The ex-dividend date was Tuesday, September 1st. McKesson's dividend payout ratio is currently 10.06%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings upgraded shares of McKesson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, September 4th. Barclays upped their target price on McKesson from $925.00 to $1,000.00 and gave the company an "overweight" rating in a report on Wednesday, August 19th. Wells Fargo & Company increased their target price on shares of McKesson from $812.00 to $933.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. UBS Group raised their price target on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, Evercore restated an "outperform" rating on shares of McKesson in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $973.44.

Insider Activity at McKesson

In other McKesson news, CEO Brian Tyler sold 8,463 shares of McKesson stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer directly owned 5,919 shares of the company's stock, valued at $4,697,081.64. The trade was a 58.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the sale, the chief accounting officer owned 521 shares of the company's stock, valued at approximately $464,445.45. This represents a 17.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,875 shares of company stock valued at $7,083,441. 0.06% of the stock is owned by insiders.

McKesson Profile

McKesson Corporation NYSE: MCK is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson's principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.